Although natural FGF-19 has strong anti-cholestasis and anti-fibrosis activities, it retains its unique tumor-promoting effect.114 NGM282, which completely retains the ability to regulate BAs without pro-tumor activity, is indicated as a new therapeutic strategy for cholestasis (Table 2).115. This evidence concerns the gene FGF19 and neoplasm.